Additionally, other work from our group identified genetic variants that were associated with both chemotherapy-induced heart failure and a decline in LVEF, and the same variants were also associated with increased TRPC6 expression in the heart, and in one case we identified a TRPC6 gain-of-function variant in a 32 year old women with breast cancer who developed heart failure following doxorubicin and trastuzumab treatment (20) and (63) suggesting that TRPC6 inhibition may be particularly appropriate as a cardioprotection strategy for men and women who carry TRPC6 risk variants. Here, TRPC6 is linked to heart failure.